SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and
commercialization of novel therapies, is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug List (NRDL) (2020 Edition) for the treatment of melanoma
by the China